Versant spinout lands $80M to go 'much broader' than the old Roche partnership that birthed it
About three years after splitting from Versant Ventures’ discovery group, Pipeline Therapeutics has landed an $80 million Series C round to go “much broader” than the Roche-partnered program that birthed it.
Versant announced Pipeline’s launch in 2018, four years after Roche agreed to pay the research tab at Versant’s Inception Sciences for remyelination work in multiple sclerosis. Remyelination involves a repair to the nerve damage that causes MS. Roche took over one of the programs, called Inception 5, and the team that helped develop it was spun out into Pipeline, including current CSO Daniel Lorrain.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.